![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
November 25, 2024
October 17, 2024
The co-chairs reflect on how the cancer research landscape has evolved over the last five years
October 17, 2024
In August, the cancer research community lost a leader in the fields of breast cancer and surgical oncology
October 17, 2024
The Patient-Reported Outcomes (PRO) Advisory Group guides study investigators on how best to include PRO measures and endpoints in clinical trials
October 17, 2024
The Journal of Clinical Oncology has published a proposal to jump-start correlative research, which is almost at a standstill
October 17, 2024
The changes aim to alleviate scheduling difficulties during the randomization step, and they introduce the new tumor test for this phase 2 trial testing radiotherapy with or without chemotherapy
October 17, 2024
Summaries of recently published ECOG-ACRIN research results
October 17, 2024
September 17, 2024
Fall Comis Symposium to focus on inflammation as a cause of cancer; ECOG-ACRIN readies for NCTN Grant resubmission
September 17, 2024
A conversation with study chair James M. Ford, MD
September 17, 2024
This innovative real-world data study is developing an infrastructure to conduct a study comparing outcomes in patients with EGFR-mutated NSCLC receiving osimertinib with or without chemotherapy and not enrolled in a clinical trial
September 17, 2024
A recent amendment expands eligibility for this phase 2 trial evaluating the use of green tea catechin pills to help prevent progression